

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



WUXI APPTEC CO., LTD.*
無錫藥明康德新藥開發股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2359)

OVERSEAS REGULATORY ANNOUNCEMENT
DISPOSAL OF CERTAIN SHARE ASSETS

Reference is made to the overseas regulatory announcement of WuXi AppTec Co., Ltd.* (無錫藥明康德新藥開發股份有限公司) (the “**Company**”) dated January 13, 2025 (the “**Announcement**”) in relation to the disposal of certain share assets. This announcement is made by the Company pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Hong Kong Listing Rules**”).

Circumstances of the Disposal

The Company, through its indirect controlled subsidiaries, holds certain shares in WuXi XDC Cayman Inc. (“**WuXi XDC**”), a company whose shares are listed on the Main Board of The Stock Exchange of Hong Kong Limited (stock code: 2268).

As disclosed and further particularized in the Announcement, on November 8, 2024 and January 10, 2025, the Company disposed of part of the shares in WuXi XDC.

On April 1, 2025, the Company continued to dispose of 50,800,000 shares in WuXi XDC via block trade (the “**Disposal**”), representing approximately 4.23% of the total issued share capital of WuXi XDC as at the date of this announcement. The aggregate transaction amount (exclusive of transaction costs including handling fees) is approximately HK\$2.178 billion, representing approximately 3.43% of the audited net assets attributable to the owners of the Company for the most recent financial year (being the year 2024).

Impact on the Company

The cash proceeds realized by the Company from the Disposal will be used to accelerate the construction of global production capacity and capability, attract and retain outstanding talents, and continuously strengthen the unique integrated CRDMO business model of the Company, so as to efficiently satisfy the growing and changing needs of global clients and patients.

The share assets being the subject of the Disposal are listed as “long-term share investments” in the financial statements of the Company. As initially calculated by the finance department of the Company in accordance with the China Accounting Standards for Business Enterprises, the aggregate realized investment gains from the Disposal is approximately RMB1.847 billion, representing over 10% of the audited net profit attributable to the owners of the Company for the most recent financial year (being the year 2024), with the impact on the net profit for the first half of 2025 being approximately RMB1.847 billion. The abovementioned data are preliminary accounting data. The Company will process the accounting treatments on the investment gains in accordance with the China Accounting Standards for Business Enterprises, the IFRS Accounting Standards and other relevant applicable regulations, and the amount of the exact impact will be subject to the results as confirmed by the auditors after the annual audit.

The Disposal and the previous disposals of shares in WuXi XDC as a whole do not constitute connected transactions or notifiable transactions of the Company under Chapter 14A and Chapter 14 of the Hong Kong Listing Rules, respectively.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
WuXi AppTec Co., Ltd.*
Dr. Ge Li
Chairman

Hong Kong, April 2, 2025

As of the date of this announcement, the Board comprises Dr. Ge Li, Dr. Minzhang Chen, Mr. Edward Hu, Dr. Steve Qing Yang and Mr. Zhaohui Zhang as executive Directors, Mr. Xiaomeng Tong and Dr. Yibing Wu as non-executive Directors and Ms. Christine Shaohua Lu-Wong, Dr. Wei Yu, Dr. Xin Zhang, Ms. Zhiling Zhan and Mr. Xuesong Leng as independent non-executive Directors.

* For identification purposes only